Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2019 Dec 5;12(12):CD004344.
doi: 10.1002/14651858.CD004344.pub7.

Treatment for avascular necrosis of bone in people with sickle cell disease

Affiliations
Meta-Analysis

Treatment for avascular necrosis of bone in people with sickle cell disease

Arturo J Martí-Carvajal et al. Cochrane Database Syst Rev. .

Abstract

Background: Avascular necrosis of bone is a frequent and severe complication of sickle cell disease and its treatment is not standardised. This is an update of a previously published Cochrane Review.

Objectives: To determine the impact of any surgical procedure compared with other surgical interventions or non-surgical procedures, on avascular necrosis of bone in people with sickle cell disease in terms of efficacy and safety.

Search methods: We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Haemoglobinopathies Trials Register, comprising references identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings. Additional trials were sought from both ongoing trial registries and the reference lists of papers identified by the search strategy. Date of the most recent search of the Group's Haemoglobinopathies Trials Register: 17 September 2019.

Selection criteria: Randomized clinical trials comparing specific therapies for avascular necrosis of bone in people with sickle cell disease.

Data collection and analysis: Each author independently extracted data and assessed trial quality. The quality of the evidence was assessed using GRADE. Given only one trial was identified, meta-analyses were not possible.

Main results: One trial (46 participants) was eligible for inclusion. After randomization eight participants were withdrawn, mainly because they declined to participate in the trial. Data were analysed for 38 participants at the end of the trial. After a mean follow-up of three years, hip core decompression and physical therapy did not show clinical improvement when compared with physical therapy alone using the score from the original trial (an improvement of 18.1 points for those treated with intervention therapy versus an improvement of 15.7 points with control therapy). We are very uncertain whether there is any difference between groups regarding major complications (hip pain, risk ratio 0.95 (95% confidence interval 0.56 to 1.60; vaso-occlusive crises, risk ratio 1.14 (95% confidence interval 0.72 to 1.80; very low quality of evidence); and acute chest syndrome, risk ratio 1.06 (95% confidence interval 0.44 to 2.56; very low quality of evidence)). This trial did not report results on mortality or quality of life.

Authors' conclusions: We found no evidence that adding hip core decompression to physical therapy achieves clinical improvement in people with sickle cell disease with avascular necrosis of bone compared to physical therapy alone. However, we highlight that our conclusion is based on one trial with high attrition rates. Further randomized controlled trials are necessary to evaluate the role of hip-core depression for this clinical condition. Endpoints should focus on participants' subjective experience (e.g. quality of life and pain) as well as more objective 'time-to-event' measures (e.g. mortality, survival, hip longevity). The availability of participants to allow adequate trial power will be a key consideration for endpoint choice.

PubMed Disclaimer

Conflict of interest statement

All authors: none known.

Figures

1
1
Methodological quality summary: review authors' judgments about each methodological quality item for each included study.
2
2
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies
3
3
Selection, enrolment and randomization
1.1
1.1. Analysis
Comparison 1 Hip core decompression and physical therapy versus physical therapy alone, Outcome 1 Pain.
1.2
1.2. Analysis
Comparison 1 Hip core decompression and physical therapy versus physical therapy alone, Outcome 2 Vaso‐occlusive crisis.
1.3
1.3. Analysis
Comparison 1 Hip core decompression and physical therapy versus physical therapy alone, Outcome 3 Acute chest syndrome.

Update of

Similar articles

Cited by

References

References to studies included in this review

NOTSCA 2006 {published and unpublished data}
    1. Aguilar C, Neumayr L, Vichinsky E. Evaluation of hip function in sickle cell patients with avascular necrosis of the hip [abstract]. Proceedings of the 23rd National Sickle Cell Disease Program Annual Meeting. 1999:55.
    1. NCT00006130. Decompression Coring Versus Conservative Therapy in Patients With Avascular Necrosis of the Hip Related to Sickle Cell Disease. https://clinicaltrials.gov/ct2/show/NCT00006130 (first posted 04 August 2000).
    1. Neumayr L, Robertson S, Aguilar C, Earles A, Jergesen H, Haberkern CM, et al. Progression of avascular necrosis of the hip in sickle cell disease: 3 year follow‐up of randomized trial of aggressive physical therapy and hip coring decompression. 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 April 8‐12; Memphis, USA. 2006. [Abstract no.: 148]
    1. Neumayr L, Robertson S, Aguilar C, Earles A, Vichinsky E, and the National Decompression Coring vs Conservative Therapy for AVN in Sickle Cell Disease Study Group. Preliminary perioperative safety data from the National Necrosis Trial in sickle cell anemia [abstract]. Proceedings of the 25th National Sickle Cell Disease Program Annual Meeting; 2001. 2001; Vol. Abstract 161.
    1. Neumayr LD, Aguilar C, Earles A, Jergesen H, Hoffinger S, Haberkern CM, et al. Final enrollment from the national avascular necrosis trial in sickle cell anemia. 27th Annual Meeting of the National Sickle Cell Disease Program; 2004 April 18‐21; Los Angeles, California. 2004:168.

References to studies excluded from this review

Al Momen 1997 {published data only}
    1. Al Momen AK, Ajarim DS, Diab AR, Harakati H, AI Abdulkareem H, Fawzi E. Clodronate in the management of acute sickle cell‐related bone pain [abstract]. Blood 1997;90(10 Suppl 1):22b.
Al‐Mousawi 2007 {published data only}
    1. Al‐Mousawi FR, Malki AA. Managing femoral head osteonecrosis in patients with sickle cell disease. Surgeon 2007;5(5):282‐9. - PubMed
Barnes 1965 {published data only}
    1. Barnes PM, Hendrickse RG, Watson‐Williams EJ. Low‐molecular‐weight dextran in treatment of bone‐pain crises in sickle‐cell disease. A double‐blind trial. Lancet 1965;2(7425):1271‐3. - PubMed
Eke 2000 {published data only}
    1. Eke FU, Obamyonyi A, Eke NN, Oyewo EA. An open comparative study of dispersible piroxicam versus soluble acetylsalicylic acid for the treatment of osteoarticular painful attack during sickle cell crisis. Tropical Medicine & International Health 2000;5(2):81‐4. - PubMed
Mukisi‐Mukasa 2009 {published data only}
    1. Mukisi‐Mukaza M, Manicom O, Alexis C, Bashoun K, Donkerwolcke M, Burny F. Treatment of Sickle cell disease's hip necrosis by core decompression: A prospective case‐control study. Orthopaedics & Traumatology, Surgery & Research 2009; Vol. 95, issue 7:498‐504. - PubMed
Opio 1972 {published data only}
    1. Opio E, Barnes PM. Intravenous urea in treatment of bone‐pain crises of sickle‐cell disease. Lancet 1972;2(7769):160‐2. - PubMed

Additional references

Aguilar 2005a
    1. Aguilar CM, Neumayr LD, Eggleston BE, Earles AN, Robertson SM, Jergesen HE, et al. Clinical evaluation of avascular necrosis in patients with sickle cell disease: Children's Hospital Oakland Hip Evaluation Scale ‐a modification of the Harris Hip Score. Archives of Physical Medicine and Rehabilitation 2005;86(7):369‐75. - PubMed
Aguilar 2005b
    1. Aguilar C, Vichinsky E, Neumayr L. Bone and joint disease in sickle cell disease. Hematology/Oncology Clinics of North America 2005;19(5):929‐41. - PubMed
Al‐Mousawi 2002
    1. Al‐Mousawi F, Malki A, Al‐Aradi A, Al‐Bagali M, Al‐Sadadi A, Booz MM. Total hip replacement in sickle cell disease. International Orthopaedics 2002;26(3):157‐61. - PMC - PubMed
Alderson 2004
    1. Alderson P. Absence of evidence is not evidence of absence. BMJ 2004;328(7438):476‐7. - PMC - PubMed
Athanassiou 2002
    1. Athanassiou‐Metaxa M, Kirkos J, Koussi A, Hatzipantelis E, Tsatra I, Economou M. Avascular necrosis of the femoral head among children and adolescents with sickle cell disease in Greece. Haematologica 2002;87(7):771‐2. - PubMed
Babhulkar 1998
    1. Babhulkar SS, Pande SK, Pande KC. Osteonecrosis of vertebral end plates in patients of sickle cell haemoglobinopathy. Journal of Bone and Joint Surgery (Br) 1998;80‐B (1S)(Suppl I):73.
Baykul 2004
    1. Baykul T, Aydin MA, Nasir S. Avascular necrosis of the mandibular condyle causing fibrous ankylosis of the temporomandibular joint in sickle cell anemia. Journal of Craniofacial Surgery 2004;15(6):1052‐6. - PubMed
Bunn 1997
    1. Bunn HF. Pathogenesis and treatment of sickle cell disease. New England Journal of Medicine 1997;337(11):762‐9. - PubMed
el‐Sabbagh 1989
    1. el‐Sabbagh AM, Kamel M. Avascular necrosis of temporomandibular joint in sickle cell disease. Clinical Rheumatology 1989;8(3):393‐7. - PubMed
Emodi 2001
    1. Emodi JI, Okoye IJ. Vertebral bone collapse in sickle cell disease: a report of two cases. East African Medicine Journal 2001;78(8):445‐6. - PubMed
Hattrup 1998
    1. Hattrup SJ. Total shoulder arthroplasty. Orthopedic Clinics of North America 1998;29(3):445‐51. - PubMed
Hebbel 2004
    1. Hebbel RP, Osarogiagbon R, Kaul D. The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy. Microcirculation 2004;11(2):129‐51. - PubMed
Hernigou 1993
    1. Hernigou P, Bachir D, Galacteros F. Avascular necrosis of the femoral head in sickle‐cell disease. Treatment of collapse by the injection of acrylic cement. Journal of Bone and Joint Surgery (Br) 1993;75(6):875‐80. - PubMed
Hernigou 2006
    1. Hernigou P, Habibi A, Bachir D, Galacteros F. The natural history of symptomatic osteonecrosis in adults with sickle‐cell disease. Journal of Bone and Joint Surgery. American volume 2006;88(12):2565‐72. - PubMed
Higgins 2003
    1. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327(7414):557‐60. - PMC - PubMed
Higgins 2011
    1. Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Ilyas 2002
    1. Ilyas I, Moreau P. Simultaneous bilateral total hip arthroplasty in sickle cell disease. Journal of Arthroplasty 2002;17(4):441‐5. - PubMed
Kim 2002
    1. Kim SK, Miller JH. Natural history and distribution of bone and bone marrow infarction in sickle hemoglobinopathies. Journal of Nuclear Medicine 2002;43(7):896‐900. - PubMed
Knox‐Macaulay 1983
    1. Knox‐Macaulay HH. Sickle cell disease in Sierra Leone: a clinical and haematological analysis in older children and adults. Annals of Tropical Medicine and Parasitology 1983;77(4):411‐9. - PubMed
Koduri 2001
    1. Koduri PR, Agbemadzo B, Nathan S. Hemoglobin S‐C disease revisited: clinical study of 106 adults. American Journal of Hematology 2001;68(4):298‐300. - PubMed
Lafforgue 2006
    1. Lafforgue P. Pathophysiology and natural history of avascular necrosis of bone. Joint Bone Spine 2006;73(5):500‐7. - PubMed
Mahadeo 2011
    1. Mahadeo KM, Oyeku S, Taragin B, Rajpathak SN, Moody K, Santizo R, et al. Increased prevalence of osteonecrosis of the femoral head in children and adolescents with sickle‐cell disease. American Journal of Hematology 2011;86(9):806‐8. [PUBMED: 21850660] - PubMed
Marouf 2003
    1. Marouf R, Gupta R, Haider MZ, Al‐Wazzan H, Adekile AD. Avascular necrosis of the femoral head in adult Kuwaiti sickle cell disease patients. Acta Haematologica 2003;110(1):11‐5. - PubMed
Meddeb 2003
    1. Meddeb N, Gandoura N, Gandoura M, Sellami S. Osteoarticular manifestations of sickle cell disease. La Tunisie Médicale 2003;81(7):441‐7. - PubMed
Neumayr 2009 [pers comm]
    1. Neumayr LN (Department of Hematology, Children's Hospital Oakland, California, USA). Query about your paper on "Femoral Head Osteonecrosis in Sickle Cell Disease" [personal communication]. Email message to: Lynne Neumayr 10 December 2009.
Pande 1998
    1. Pande KC, Pand S, Babhulkar SS. Osteonecrosis of humeral head in sickle cell haemoglobinopathy. Journal of Bone and Joint Surgery (Br) 1998;80‐B (1S)(Suppl I):73.
Pauling 1949
    1. Pauling L, Itano HA, Singer SJ, Wells IC. Sickle cell anemia, a molecular disease. Science 1949;110:543‐6. - PubMed
Plancher 1997
    1. Plancher KD, Razi A. Management of osteonecrosis of the femoral head. The Orthopedic Clinics of North America 1997;28(3):461‐77. - PubMed
Powars 2002
    1. Powars DR, Hiti A, Ramicone E, Johnson C, Chan L. Outcome in hemoglobin SC disease: a four‐decade observational study of clinical, hematologic, and genetic factors. American Journal of Hematology 2002;70(3):206‐15. - PubMed
RevMan 2011 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
Sadat‐Ali 1994
    1. Sadat‐Ali M, Ammar A, Corea JR, Ibrahim AW. The spine in sickle cell disease. International Orthopaedics 1994;18(3):154‐6. - PubMed
Sathappan 2006
    1. Sathappan SS, Ginat D, Cesare PE. Multidisciplinary management of orthopedic patients with sickle cell disease. Orthopedics 2006;29(12):1094‐101. - PubMed
Saunthararajah 2004
    1. Saunthararajah Y, Vichinsky EP, Embury SH. Sickle cell disease. Hoffman: Hematology: Basic Principles and Practice. Churchill Livingstone, 2004.
Serjeant 1992
    1. Serjeant GR. Sickle Cell Disease. 2nd Edition. New York: Oxford University Press, 1992.
Serjeant 2001
    1. Serjeant GR. The emerging understanding of sickle cell disease. British Journal of Haematology 2001;112(1):3‐18. - PubMed
Steinberg 2006
    1. Steinberg MH. Pathophysiologically based drug treatment of sickle cell disease. Trends in Pharmacological Sciences 2006;27(4):204‐10. - PubMed
Stuart 2004
    1. Stuart MJ, Nagel RL. Sickle‐cell disease. Lancet 2004;364(9442):1343‐60. - PubMed
Vichinsky 1999
    1. Vichinsky EP, Neumayr LD, Haberkern C, Earles AN, Eckman J, Koshy M, et al. The perioperative complication rate of orthopedic surgery in sickle cell disease: report of the National Sickle Cell Surgery Study Group. American Journal of Hematology 1999;62(3):129‐38. - PubMed
Weatherall 2006
    1. Weatherall D, Akinyanju O, Fucharoen S, Olivieri N, Musgrove P. Inherited Disorders of Hemoglobin. Disease Control Priorities in Developing Countries. 2nd edition. Washington (DC): The World Bank and Oxford University Press, 2006.
Zavala 2006 [Computer program]
    1. Zavala D, Martí A, Peña‐Martí G, Comunián G. Sheet to enter data for performing a Cochrane review (www.cochrane.fcs.uc.edu.ve/hrs/). Valencia, Venezuela: Universidad de Carabobo, 2006.

References to other published versions of this review

Martí‐Carvajal 2004
    1. Martí‐Carvajal A, Dunlop R, Agreda‐Perez L. Treatment for avascular necrosis of bone in people with sickle cell disease. Cochrane Database of Systematic Reviews 2004, Issue 4. [DOI: 10.1002/14651858.CD004344.pub3] - DOI - PubMed
Martí‐Carvajal 2009
    1. Martí‐Carvajal AJ, Sola I, Agreda‐Perez LH. Treatment for avascular necrosis of bone in people with sickle cell disease. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD004344.pub3; PUBMED: 19588352] - DOI - PubMed
Martí‐Carvajal 2014
    1. Martí‐Carvajal AJ, Solà I, Agreda‐Pérez LH. Treatment for avascular necrosis of bone in people with sickle cell disease. Cochrane Database of Systematic Reviews 2014, Issue 7. [DOI: 10.1002/14651858.CD004344.pub5] - DOI - PubMed
Martí‐Carvajal 2016
    1. Martí‐Carvajal AJ, Solà I, Agreda‐Pérez LH. Treatment for avascular necrosis of bone in people with sickle cell disease. Cochrane Database of Systematic Reviews 2016, Issue 8. [DOI: 10.1002/14651858.CD004344.pub6] - DOI - PubMed

Publication types